[go: up one dir, main page]

CR11362A - BISPHOSPHONATES FOR RENT FROM 2 TO 5 CAROMON-IMIDAZOL ATOMS - Google Patents

BISPHOSPHONATES FOR RENT FROM 2 TO 5 CAROMON-IMIDAZOL ATOMS

Info

Publication number
CR11362A
CR11362A CR11362A CR11362A CR11362A CR 11362 A CR11362 A CR 11362A CR 11362 A CR11362 A CR 11362A CR 11362 A CR11362 A CR 11362A CR 11362 A CR11362 A CR 11362A
Authority
CR
Costa Rica
Prior art keywords
imidazol
caromon
bisphosphonates
rent
atoms
Prior art date
Application number
CR11362A
Other languages
Spanish (es)
Inventor
Sven Weiler
Leo Widler
Jean-Michael Rondeau
Simona Cotesta
Wolfgang Jahnke
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39154111&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR11362(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR11362A publication Critical patent/CR11362A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503Five-membered rings
    • C07F9/6506Five-membered rings having the nitrogen atoms in positions 1 and 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen acidos [(imidazol-1-il)-1-hidroxi-1-fosfono-etil] -fosfonicos sustituidos por alquilo de 2 a 5 atomos de carbono, asi como metodos o procesos para su fabricacion, su uso en la fabricacion de formulaciones farmaceuticas, su uso en el tratamiento de enfermedades, metodos para utilizarlos en el tratamiento de enfermedades, formulaciones farmaceuticas que los abarcan, y/o los compuestos para utilizarse en el tratamiento de enfermedades.[(Imidazol-1-yl) -1-hydroxy-1-phosphono-ethyl] -phosphonic acids substituted by alkyl of 2 to 5 carbon atoms, as well as methods or processes for their manufacture, their use in the manufacture of Pharmaceutical formulations, their use in the treatment of diseases, methods for use in the treatment of diseases, pharmaceutical formulations that cover them, and / or the compounds for use in the treatment of diseases.

CR11362A 2007-11-30 2010-04-09 BISPHOSPHONATES FOR RENT FROM 2 TO 5 CAROMON-IMIDAZOL ATOMS CR11362A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07122016 2007-11-30

Publications (1)

Publication Number Publication Date
CR11362A true CR11362A (en) 2010-06-14

Family

ID=39154111

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11362A CR11362A (en) 2007-11-30 2010-04-09 BISPHOSPHONATES FOR RENT FROM 2 TO 5 CAROMON-IMIDAZOL ATOMS

Country Status (24)

Country Link
US (2) US7977323B2 (en)
EP (1) EP2225252B1 (en)
JP (1) JP5244917B2 (en)
KR (1) KR20100092035A (en)
CN (1) CN101835787A (en)
AR (1) AR069437A1 (en)
AU (1) AU2008328797B2 (en)
BR (1) BRPI0819902A2 (en)
CA (1) CA2701516A1 (en)
CL (1) CL2008003545A1 (en)
CO (1) CO6280421A2 (en)
CR (1) CR11362A (en)
EA (1) EA201000860A1 (en)
EC (1) ECSP10010321A (en)
ES (1) ES2386851T3 (en)
IL (1) IL204657A0 (en)
MA (1) MA31895B1 (en)
MX (1) MX2010005786A (en)
NZ (1) NZ584219A (en)
PE (1) PE20091038A1 (en)
TN (1) TN2010000138A1 (en)
TW (1) TW200932248A (en)
WO (1) WO2009068567A1 (en)
ZA (1) ZA201001992B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009232033A1 (en) * 2008-04-04 2009-10-08 Novartis Ag Pharmaceutical composition with bisphosphonate
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
CA2769633C (en) 2009-07-31 2017-06-06 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US8816082B2 (en) 2010-05-28 2014-08-26 The Royal Institution For The Advancement Of Learning/Mcgill University Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
US9290526B2 (en) 2010-05-28 2016-03-22 The Royal Institution For The Advancement Of Learning/Mcgill University Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
CN102659840B (en) * 2012-05-10 2013-08-14 苏州普瑞诺药物技术有限公司 Imidazole diphosphonie acid compound and pharmaceutically-acceptable salt and medicinal application thereof
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
EP3698797A1 (en) 2017-10-16 2020-08-26 Tsinghua University Mevalonic acid pathway inhibitor and pharmaceutical composition thereof
CN112980809B (en) * 2021-03-17 2023-04-11 云南中烟工业有限责任公司 Tobacco farnesyl pyrophosphate synthase gene and application thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE72816T1 (en) 1986-11-21 1992-03-15 Ciba Geigy Ag NEW SUBSTITUTE ALKANEDIPHOSPHONE ACIDS.
HU215124B (en) * 1991-02-26 1998-09-28 Norwich Eaton Pharmaceuticals, Inc. Process for producing synergetic pharmaceutical compositions containing estrogen and diphosphonate for treating osteoporosis
GB9324143D0 (en) 1993-11-24 1994-01-12 Schering Agrochemicals Ltd Triazole phosphonate pesticides
GB0029018D0 (en) * 2000-11-28 2001-01-10 Strakan Group Plc Dermatological formulations
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
WO2008128056A1 (en) 2004-10-08 2008-10-23 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps
WO2006039721A2 (en) 2004-10-08 2006-04-13 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
US20100047306A1 (en) 2006-10-05 2010-02-25 Novartis Ag Pharmaceutical compositions comprising bisphosponates
JP2010522765A (en) 2007-03-28 2010-07-08 アレイ バイオファーマ、インコーポレイテッド Imidazo [1,2-A] pyridine compounds as receptor tyrosine kinases

Also Published As

Publication number Publication date
EP2225252B1 (en) 2012-06-27
ECSP10010321A (en) 2010-08-31
AU2008328797A1 (en) 2009-06-04
JP2011504908A (en) 2011-02-17
US7977323B2 (en) 2011-07-12
PE20091038A1 (en) 2009-08-19
KR20100092035A (en) 2010-08-19
ZA201001992B (en) 2010-12-29
US20090143337A1 (en) 2009-06-04
WO2009068567A1 (en) 2009-06-04
MX2010005786A (en) 2010-06-09
BRPI0819902A2 (en) 2015-05-19
CA2701516A1 (en) 2009-06-04
CN101835787A (en) 2010-09-15
TW200932248A (en) 2009-08-01
MA31895B1 (en) 2010-12-01
AU2008328797B2 (en) 2011-11-03
JP5244917B2 (en) 2013-07-24
ES2386851T3 (en) 2012-09-03
NZ584219A (en) 2012-03-30
CL2008003545A1 (en) 2009-06-05
US20110224173A1 (en) 2011-09-15
EA201000860A1 (en) 2010-12-30
EP2225252A1 (en) 2010-09-08
TN2010000138A1 (en) 2011-09-26
AR069437A1 (en) 2010-01-20
CO6280421A2 (en) 2011-05-20
IL204657A0 (en) 2010-11-30

Similar Documents

Publication Publication Date Title
CR11362A (en) BISPHOSPHONATES FOR RENT FROM 2 TO 5 CAROMON-IMIDAZOL ATOMS
UY29004A1 (en) SUBSTITUTED DERIVED COMPOUNDS OF ACIDS, GLYCIN AND ALANINE; PROCEDURE FOR PREPARATION AND USE.
UY33817A (en) ? NEW BENCYLIC OXINDOLPIRIMIDINES ?.
CR20120264A (en) COMPOUNDS
AR063628A1 (en) USEFUL PIRIDINONE COMPOUNDS FOR CANCER TREATMENT
CR20110326A (en) PIRAZINA COMPOUNDS AS PHOSPHODESTERASE INHIBITORS 10
MX337152B (en) Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators.
ECSP088749A (en) TETRAHYDROPIRIDOTIENOPIRIMIDINE COMPOUNDS AND PROCEDURES FOR THE SAME USE
ECSP10010335A (en) PIRROLO-PIRIMIDINAS AND PIRROLO-PIRIDINAS
UY30094A1 (en) CHEMICAL COMPOUNDS
CO6630189A2 (en) Heterocyclic nitrogen compounds useful as pde10 inhibitors
CO6321189A2 (en) BENCEN-SULFONAMIDE TIAZOL AND OXAZOL COMPOUNDS
UY33337A (en) SUBSTITUTED DERIVATIVES OF 1H-PIRAZOL [3,4-d] PYRIMIDINE AS INHIBITORS OF PHOSFOINOSITIDE 3-KINASES
CL2011001967A1 (en) Compounds derived from substituted carboxamide-azaheterocyclic, p70s6k inhibitors, preparation process thereof; pharmaceutical composition that includes them; and its use in the treatment of inflammatory diseases and cancer; Pharmaceutical kit
CO6450612A2 (en) SUBSTITUTED 1-CYANOETHYLETHYCLIC CARBOXAMIDE 750 COMPOUNDS
CU20120013A7 (en) OXACINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
CL2012002487A1 (en) Compounds derived from imidazo [1,2-a] pyrazine, pde10 inhibitors; pharmaceutical composition that includes them; process to prepare the pharmaceutical composition; Useful for the treatment of neurological, psychiatric or metabolic diseases such as schizophrenia, parkinson and diabetes, among others.
CO6321136A2 (en) INDAZOL DERIVATIVES REPLACED BY AXADIAZOL FOR USE AS SPPHINGOSINE 1 PHOSPHATE AGONISTS (S1P)
CO6361849A2 (en) DERIVATIVES OF N-CICLOALQUIL-NBIFENILMETIL-CARBOXAMIDA FUNGICIDAS
ECSP099490A (en) METHODS OF MANUFACTURE AND USE OF COMPOUNDS AND COMPOSITIONS
NI201300072A (en) HETEROARYL DERIVATIVES AS NACHR ALPHA 7 MODULATORS
CO6382089A2 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES CAUSED BY A B-AMYLOID AND SINUCLEINOPATIAS
ECSP11010786A (en) 5-ALQUINIL-PYRIMIDINS
UY29223A1 (en) PHENOXYACETIC ACIDS REPLACED, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION
CO6341625A2 (en) DERIVATIVES OF INDOL AS ANTI-CANCER AGENTS